1200 PAGE MILL RD, PALO ALTO, CA
Zenkuda and tabirafusp-ted Meet Key Endpoints in DAYBREAK Trial for wAMD.
Announces Recent Business Highlights and Second Quarter 2026 Financial Results
Election of Class II Directors at Kodiak Sciences Inc. Annual Meeting
Announces Recent Business Highlights and First Quarter 2026 Financial Results
Annual Report to Security Holders
Financial Results, Press Release
Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Kodiak Sciences Enters Underwriting Agreement for Public Offering of Shares
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload